

USSN 09/645,967 VE WAR sylectituted or 7 2003

R²⁸ and R⁴³ are independently selected from the group consisting of H and a symplectic structure.

unsubstituted aliphatic or acyl moiety;

one of R^{7a} and R^{7b} is H and the other is halo, -R^A, -OR^A, -SR^A, -OC(O)R^A, -OC(O)NR^AR^B, -¹⁶⁰⁰/2900 NR^AR^B, -NR^BC(O)R^A, -NR^BC(O)OR^A, -NR^BSO2R^A, or -NR^BSO2NR^AR^B'; or R^{7a} and R^{7b} taken together, are H in the tetraene moiety:

where R^A is H or a substituted or unsubstituted aliphatic, heteroaliphatic, aryl, or heteroaryl moiety;

where R^B is H, OH or a substituted or unsubstituted aliphatic, heteroaliphatic, aryl, or heteroaryl moiety;

where a heteroaliphatic moiety is an aliphatic moiety which contains one or more oxygen, sulfur, nitrogen, phosphorous or silicon atoms;

where an aryl moiety is a mono- or polycyclic unsaturated moiety having 3-14 carbon atoms; and where a heteroaryl moiety is a mono- or polyheterocyclic unsaturated moiety having 3-14 carbon atoms;

or a pharmaceutically acceptable salt, ester, carbamate, metabolite or pro-drug thereof; or a pharmaceutically acceptable salt of such ester or carbamate.

20. (Twice amended) A compound of the formula:

wherein

n is 1 or 2;

 R^{28} and R^{43} are independently selected from the group consisting of H and a substituted or unsubstituted aliphatic or acyl moiety;

one of R^{7a} and R^{7b} is H and the other is halo, $-R^A$, $-OR^A$, $-SR^A$, $-OC(O)R^A$, $-OC(O)NR^AR^B$, $-NR^BC(O)R^A$, $-NR^BC(O)OR^A$, $-NR^BSO2R^A$, or $-NR^BSO2NR^AR^B$; or R^{7a} and R^{7b} taken together, are H in the tetraene moiety:

where R^A is H or a substituted or unsubstituted aliphatic, heteroaliphatic, aryl, or heteroaryl moiety;

where R^B is H, OH or a substituted or unsubstituted aliphatic, heteroaliphatic, aryl, or heteroaryl moiety;

where a heteroaliphatic moiety is an aliphatic moiety which contains one or more oxygen, sulfur,